PharmaTelevision - Roche Seeks Out CNS Prospects

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Roche Seeks Out CNS Prospects

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

The formation and management of dynamic partnerships has helped Roche to make a name for itself in several therapeutic areas. Sarah Holland describes her aim to make sure that one of these areas is CNS through developing their current clinical pipelines and by finding external innovations that compliment their internal projects. She explains that with all the different science she sources the deal structures vary widely, making sure that the product has the best chance of success.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

The structure of CNS pharma partnering within Roche

Fintan Walton:

Hello and welcome to PharmaVentures business review here in Melbourne Australia. On this show I have Sarah Holland who is Global Head of CNS partnering at Roche in Basel, Switzerland. Welcome to the Show.

Sarah Holland:

Thank you.

Fintan Walton:

You are part of the Pharma partnering group which goes out to do set up alliances with Biotechnology companies you know the pharmaceutical companies. So before we start on this your specific role can you tell us a little bit about how a Pharma partnering actually structured in within Roche because about just a year ago you restructured, so maybe you could help us understand the structure.

Sarah Holland:

Okay. Well the Pharma partnering group in Roche is a group of about 90 people who work globally. We are based in Basel not only we take in care of we went Shanghai office, so we work as a global team. So I always say to people if you got hold of one person if am a partner will get you to the right person and we are actually sort of Biotech science when you have about 90 people's so it's not so scary as an 80,000 global organization. And we look after the whole precisive element function right from platform technologies in the late future strategic alliances, invests and acquisitions and so on, in licensing, out licensing. About a year ago we actually reorganized our R&D function around five disease biology areas so Oncology, Metabolism,Virology, Inflammation and CNS and to match that Pharma partnering with a small organization and created these new roles in which mine is one so I am the global head of CNS partnering and I look after all to the CNS are edged at which is developed partnering, sit on the management team with alongside me we still have people in charge of the transactions process, the alliance management function and technology acquisitions and so on so we still have the same people doing the same jobs we've slightly reconfigured.

Fintan Walton:

Right so the key thing there is to make sure it's properly aligned with the various therapeutic areas within Rocheso that means did you got access to all those individuals right straight through the research and development process?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Sarah Holland

Global Head for CNS Partnering

Sarah Holland is the Global Head for CNS Partnering at Pharma Partnering, Roche Pharmaceuticals based in Basel, Switzerland. Prior to joining Roche, Sarah Holland was Global Brand Director at AstraZeneca for a hormonal agent for breast cancer during US and EU launch. She held various commercial and strategic roles over her ten years there including Global Strategic Planning Manager for early compounds, Pricing Strategist and Health Economist. Sarah's interest in the CNS field dates back to the start of her industry career at Amersham International (now GE Healthcare), where she was International Product Manager for an innovative agent for imaging brain blood flow. Sarah Holland gained her MBA from Manchester Business School, where she was a Visiting Fellow until 2004, and her PhD and first degree at Oxford University.

Roche

Founded in 1896 and headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. The Roche Group's Pharmaceuticals Division is made up of Roche Pharmaceuticals represented in over 150 countries, and majority shareholdings in Genentech in the United States and Chugai in Japan. Rochecooperates closely with Genentech and Chugai and also maintains licensing or other collaborative agreements with more than 80 companies around the world, giving the Roche wide access to promising experimental medicines and cutting-edge technologies.